Menu Search
Equities

Boston Scientific Corp

BSX:DUS

Boston Scientific Corp

Actions
  • Price (EUR)66.50
  • Today's Change-0.50 / -0.75%
  • Shares traded5.00
  • 1 Year change+40.41%
  • Beta--
Data delayed at least 15 minutes, as of Apr 30 2024 18:31 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company’s segments include MedSurg and Cardiovascular. The MedSurg segment includes Endoscopy, Urology and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a broad range of gastrointestinal (GI) and pulmonary conditions with less invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. The Cardiovascular segment includes Cardiology and Peripheral Interventions. The Company's Interventional Cardiology Therapies business develops and manufactures technologies for diagnosing and treating coronary artery disease and aortic valve conditions.

  • Revenue in USD (TTM)14.71bn
  • Net income in USD1.77bn
  • Incorporated1979
  • Employees48.00k
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		BSX:NYQ since
announced		Transaction
value
Axonics IncAnnounced08 Jan 202408 Jan 2024Announced24.16%3.67bn
Relievant Medsystems IncDeal completed19 Sep 202319 Sep 2023Deal completed36.25%850.00m
Data delayed at least 15 minutes, as of May 01 2024 21:10 BST.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.